Abstract-We explored the role of asymmetrical dimethylarginine (ADMA) as a cause of endothelial dysfunction induced by systemic inflammation. In vitro data suggest that ADMA bioavailability is regulated by proinflammatory stimuli, but it is unclear whether ADMA is a link between inflammation and endothelial dysfunction in humans. In study 1 we recruited 351 patients with coronary artery disease (CAD) and 87 healthy controls. In study 2 we recruited 69 CAD, 69 healthy, and 10 patients with rheumatoid arthritis, whereas in study 3, 22 healthy and 70 CAD subjects were randomly assigned to Salmonella typhii vaccination (nϭ11 healthy and nϭ60 CAD) or placebo (nϭ11 healthy and nϭ10 CAD). Circulating interleukin 6/ADMA and flow-mediated dilation (FMD) were measured at 0 and 8 hours. In study 1, ADMA was inversely correlated with FMD in healthy individuals and CAD patients (PϽ0.0001 for both). However, interleukin 6 was inversely correlated with FMD (PϽ0.0001) in healthy subjects but not in CAD patients. The positive correlation between ADMA and interleukin 6 was stronger in healthy (rϭ0.515; PϽ0.0001) compared with CAD (rϭ0.289; Pϭ0.0001) subjects. In study 2, both patients with rheumatoid arthritis and CAD had higher interleukin 6 (PϽ0.0001) and ADMA (Pϭ0.004) but lower FMD (Pϭ0.001) versus healthy subjects. In study 3, vaccination increased interleukin 6 in healthy (PϽ0.001) and CAD (PϽ0.001) subjects. FMD was reduced in healthy subjects (PϽ0.05), but its reduction in CAD was borderline. Vaccination increased ADMA only in healthy subjects (PϽ0.001). Systemic, low-grade inflammation leads to increased ADMA that may induce endothelial dysfunction. This study demonstrated that ADMA may be a link between inflammation and endothelial dysfunction in humans. (Hypertension. 2011;57:00-00.) • Online Data Supplement Key Words: ADMA Ⅲ endothelium Ⅲ inflammation Ⅲ interleukin 6 Ⅲ atherosclerosis Ⅲ coronary artery disease T he development of endothelial dysfunction is considered to be the initial step in atherogenesis. 1 A healthy endothelium is responsible for NO generation through oxidation of L-arginine by endothelial NO synthase (eNOS). 1 NO maintains vascular tone and acts, per se, as an important intracellular messenger, inducing divergent anti-inflammatory, antithrombotic, and antiapoptotic effects. 1 Asymmetrical dimethylarginine (ADMA), an endogenous L-arginine analog, has been associated with impaired endothelial function in humans. 2 ADMA has also been associated with eNOS uncoupling that results in increased eNOSderived superoxide production in human vessels. 2 Clinical evidence suggests that ADMA plasma levels are associated with endothelial function, particularly in patients with coronary atherosclerosis 3 or atherosclerosis risk factors, 4 whereas this association is significant but weak in healthy individuals. 5 Furthermore, in prospective studies, plasma ADMA has been independently associated with clinical outcome and mortality in diabetic subjects and patients with atherosclerosis. 6 ADMA is derived from the methylation of arginine residues within proteins by the activity of redox-sensitive S-adenosylmethionine-dependent protein arginine N-methyltransferases. 7 Increased oxidative stress upregulates protein arginine N-methyltransferase expression and ADMA synthesis. On the other hand, pro-oxidant and proinflammatory stimuli inhibit dimethylarginine dimethyl-aminohydrolase activity, the enzymes responsible for ADMA degradation in cell culture studies. 8 These data support the clinical observations that ADMA plasma levels are elevated in subclinical inflammation states, such as in patients with multiple risk factors for atherosclerosis. 9 However, our knowledge regarding the ef-
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In the present study we examined the links among systemic inflammation, circulating ADMA levels, and endothelial function in different inflammatory milieu states. In addition, using a clinical model of acute inflammation, we examined whether acute inflammation modifies circulating ADMA and endothelial function in humans.
Methods

Population and Study Protocol
The study consisted of 3 arms, described below.
Study Arm 1
A population of 351 patients with coronary atherosclerosis (angiographically documented coronary artery disease [CAD] with Ͼ1 coronary vessel with stenoses Ͼ50%) and 87 healthy individuals of similar age were included in this study arm. Exclusion criteria were any inflammatory, infective, liver or renal failure, malignancy, acute coronary event during the last 2 months or clinically overt heart failure. Patients receiving nonsteroidal anti-inflammatory drugs, dietary supplements of folic acid, or antioxidant vitamins were also excluded. All of the patients discontinued nitrate treatment Ն24 hours before sample intake. Demographic characteristics of the patients are presented in the online Data Supplement, Table S1 (please see http://hyper.ahajournals.org). Endothelial function was evaluated by studying flow-mediated dilation (FMD) in the brachial artery, whereas blood samples were also obtained from all of the subjects. The protocol was performed after a 12-hour fasting period. This study arm was designed to search for associations among ADMA, interleukin (IL) 6, and FMD within each group (CAD and healthy individuals, respectively). However, the relatively small number of healthy individuals may not be representative of the entire healthy population, and this is a limitation of this design, 10 -12 not allowing any between-group comparisons.
Study Arm 2
To examine whether chronic inflammation is a key regulator of ADMA levels and endothelial function in atherosclerosis, we then compared the impact of 2 different inflammatory conditions, CAD and chronic rheumatoid arthritis (RA), on serum ADMA and FMD. To achieve that, we compared serum ADMA and FMD between 69 patients with CAD and 69 healthy controls (matched for age and sex to CAD) and 10 patients with RA of similar age (Table S1 ). RA and healthy individuals had no evidence for CAD, defined by medical history, clinical examination, ECG, cardiac echocardiography, and negative exercise stress test within the previous 6 months. Exclusion criteria for all of the groups in this arm were any inflammatory, infective, liver or renal failure, malignancy, acute coronary event during the last 2 months or clinically overt heart failure. Patients receiving nonsteroidal anti-inflammatory drugs, dietary supplements of folic acid, or antioxidant vitamins were also excluded. Endothelial function was evaluated by studying FMD in the brachial artery, whereas blood samples were also obtained from all of the subjects after a 12-hour fasting period.
Study Arm 3
We then examined whether the association between inflammation and ADMA observed in study arms 1 and 2 is causal. To achieve that, we performed a study in which 22 healthy young individuals and 70 patients with CAD were randomly allocated into 2 groups that received either vaccination with Salmonella typhi capsular polysaccharide (0.025 mg, Typhim Vi, Pasteur Merieux MSD, France; nϭ11 for healthy and nϭ60 for CAD) or placebo (normal saline; nϭ11 for healthy and nϭ10 for CAD) intramuscularly, in a double-blind design (Table S2 ). The exclusion criteria were any inflammatory, infective, liver or renal disease; malignancy; acute coronary event during the last 2 months; or clinically overt heart failure. Patients receiving nonsteroidal anti-inflammatory drugs, dietary supplements of folic acid, or antioxidant vitamins were also excluded.
Subjects had fasted for Ն12 hours and had abstained from caffeine, ethanol, and flavonoid-containing beverages intake for the same period of time. At baseline, FMD of the brachial artery was estimated, and blood samples were obtained. Then all of the subjects received either S typhi capsular polysaccharide vaccine or placebo that was injected into the deltoid muscle of the subject's nondominant arm, as described previously. 13 FMD and blood sampling were repeated at 8 hours to examine the causal effect of inflammation on ADMA levels. This time point was defined based on pilot data (data not shown) in 5 healthy individuals demonstrating that, 8 hours after vaccination, FMD is at its minimum level, whereas this effect is smaller at 12 hours and disappears at 24 hours.
All 3 of the studies were approved by the institutional ethics committee, and each patient gave an informed written consent. All of the studies adhered to the principles of the Declaration of Helsinki and the US federal regulations, whereas all of the procedures followed were in accordance with the institutional guidelines.
Assessment of Endothelial Function
FMD and endothelium-independent vasodilatation of the brachial artery were measured by using a validated ultrasound technique (see online Data Supplement).
Blood Sampling and Serum Lipid Measurements
Venous blood samples were centrifuged at 2000g at 4°C for 15 minutes, and plasma or serum was collected and stored at Ϫ80°C until assayed. Serum lipid levels were measured by using a chromatographic enzymic method in a Technicon automatic analyzer RA-1000 (Dade Behring, Marburg, Germany).
Measurement of Systemic Inflammatory Markers and ADMA
Serum IL-6 and ADMA were measured by ELISA (please see online Data Supplement for further details).
Statistical Analysis
Statistical methods are described in the online Data Supplement.
Results
Associations Among IL-6, ADMA, and Endothelial Function
We first examined the associations between plasma ADMA and FMD in 2 separate populations, healthy individuals and patients with CAD. We observed that plasma ADMA was strongly negatively associated with FMD in both patients with CAD and healthy individuals ( Figure 1) .
Similarly, plasma IL-6 was negatively associated with FMD in healthy individuals but not in patients with CAD ( Figure 1 ). In line with these observations, we also observed a strong positive association between plasma ADMA and serum IL-6 in healthy individuals but only a borderline, weak association between these 2 biomarkers in patients with CAD ( Figure 1) . In multivariable analysis, the independent predictors for FMD in CAD patients were log(ADMA) ( 
Effect of the Underlying Inflammatory Status on FMD and ADMA Levels
To further explore this inconsistency between the observed associations in healthy individuals and patients with CAD, we then compared the impact of systemic inflammation on ADMA and endothelial function by comparing plasma ADMA and FMD among healthy individuals, patients with CAD, and patients with RA. As expected, both RA and CAD were associated with significantly higher IL-6 levels compared with healthy individuals, whereas patients with RA had significantly higher IL-6 levels compared with patients with CAD ( Figure 2 ). Importantly, we observed that both inflammatory conditions, RA and CAD, were associated with a significant reduction of FMD compared with healthy individuals ( Figure 2 ). Moreover, serum ADMA was similarly elevated in both RA and CAD (Figure 2 ), suggesting that chronic inflammation leads to an elevation of serum ADMA, which may contribute to the development of endothelial dysfunction in these subjects. The absolute diameters of the brachial artery were not different among the groups and did not account for any of the observed differences in FMD among the 3 study groups (Table S1 ).
Causal Association Among Inflammation, ADMA, and Endothelial Function
To further examine whether inflammation induces an elevation of ADMA levels that may mediate the inflammationrelated endothelial dysfunction, we induced inflammation (by using S typhi vaccination) in healthy, young individuals (low baseline inflammatory status model) and patients with CAD (high baseline inflammatory status model). We observed that acute inflammation induced a significant elevation of IL-6 in both healthy young individuals and patients with established coronary atherosclerosis (Figure 3) . Importantly, acute inflammation induced a significant reduction of FMD in parallel with an elevation of serum ADMA in healthy individuals (Figure 3) . However, acute inflammation induced only a borderline reduction of FMD despite the significant elevation of IL-6 in CAD patients, whereas ADMA remained unchanged after vaccination in this population (Figure 3) . The absolute diameters of the brachial artery were not different between the groups and did not account for any of the effects of acute inflammation on FMD (Table S2 ). CAD; B) . However, interleukin 6 (IL-6) levels were inversely correlated with FMD in healthy individuals (C) but not in patients with CAD (D). Finally, the positive correlation between ADMA and IL-6 was much stronger in healthy individuals (E) than CAD patients (F).
Discussion
Circulating ADMA levels have been associated with increased cardiovascular risk, 14 although they have also been associated with disease severity and major adverse cardiovascular events. 15 ADMA is an endogenous inhibitor of eNOS and predicts endothelial dysfunction in healthy individuals 5, 16 and patients with peripheral arterial disease. 3 As we have demonstrated in the past, 2 plasma ADMA levels are negatively associated with endothelial function in patients with advanced atherosclerosis. 2 In the present study, we demonstrated that circulating ADMA is an independent predictor of endothelial dysfunction in healthy subjects, whereas it is a rather weak predictor of endothelial dysfunction in patients with established CAD. Given this observation, we then examined the hypothesis that the background inflammation in CAD patients modifies the role of ADMA in the development of endothelial dysfunction.
Systemic inflammation has been clearly associated with endothelial dysfunction, leading to atherogenesis. 17 In experimental animal models, proinflammatory stimulation activates protein arginine methyltransferases enhancing ADMA synthesis, although it also downregulates dimethylarginine dimethyl hydrolase, reducing in this way ADMA's degradation. 18 It is, therefore, likely that ADMA may be a key molecule mediating the association between inflammation and endothelial dysfunction, although the causality of such an association in humans has not been demonstrated.
In cross-sectional studies, ADMA levels are positively associated with inflammatory markers such as C-reactive protein in acute inflammatory conditions such as septic shock 19 and in chronic inflammatory diseases such as systemic lupus erythematosus. 20 Finally, in subjects with evidence of subclinical inflammation, circulating inflammatory biomarkers are positively associated with ADMA 21 and inversely correlated with FMD, 5, 17 implying that ADMA may contribute to endothelial dysfunction in these clinical conditions without, however, any of these studies to prove a causal association.
In the present study we demonstrate that circulating IL-6 is associated with both ADMA levels and endothelial dysfunction in healthy subjects, whereas in multivariable analysis, the interaction between IL-6 and FMD depended on circulating ADMA. On the other hand, the association between IL-6 and CAD; B) . However, despite the striking reduction of flow-mediated dilation (FMD) in the healthy individuals group after vaccination (C), the reduction of FMD in the CAD group was borderline, and the change was not significantly different compared with placebo (D). Similarly, acute inflammation increased ADMA levels in healthy individuals (E) but not in patients with CAD (F). Values are presented as median (25th to 75th) percentile. *PϽ0.05; **PϽ0.01 vs 0 hours; P ANOVA was derived from 2-way ANOVA for repeated measurements with timeϫgroup interaction.
ADMA was weaker in CAD patients, whereas ADMA was again the only predictor of FMD independent of IL-6. Importantly, by using a model of chronic inflammation (patients with RA), we demonstrate that a high baseline inflammatory status is accompanied by elevated ADMA and endothelial dysfunction, even in the absence of atherosclerosis.
In cell culture models, proinflammatory mediators such as tumor necrosis factor-␣ or angiotensin II promote ADMA accumulation by inhibiting activity of dimethylarginine dimethyl-aminohydrolase. 18 However, in acute infections (a model of lipopolysaccharide-mediated inflammation in humans), ADMA was increased by the end of infection period, 22 suggesting that the type of underlying inflammatory stimuli plays a crucial role in ADMA regulation. Therefore, the causal association among low-grade inflammation, ADMA, and endothelial dysfunction needs to be clarified.
In the present study, we demonstrate for the first time in humans that acute inflammation induced by S typhii vaccination increases circulating ADMA and leads to a parallel impairment of endothelial function in healthy individuals. However, in patients with CAD, baseline inflammation and circulating ADMA are higher, and acute inflammation has only a moderate effect on endothelial function and fails to change ADMA levels, despite the striking elevation of circulating IL-6. Although we demonstrate an effect of acute inflammation on both ADMA and FMD, the direct causal effect of ADMA on FMD can only be implied; other mechanisms, such as the inflammation-induced elevation of NADPH-oxidase 23 or the depletion of L-arginine because of reduced de novo synthesis 24 could also account for the effect of inflammation on endothelial function.
In conclusion, we demonstrate that ADMA levels are increased in the presence of chronic inflammation (in the setting of advanced atherosclerosis or rheumatoid arthritis), and ADMA is closely associated with IL-6 levels. In addition, we demonstrate for the first time that acute inflammation induces a parallel elevation of serum ADMA and impairment of endothelial function in healthy individuals, implying that ADMA may mediate the development of inflammationrelated endothelial dysfunction in these subjects. Further studies are required to explore whether ADMA could be used as an alternative therapeutic target to prevent the proatherogenic effects of low-grade inflammation in humans.
Perspectives
In this study we demonstrate that systemic inflammation is associated with increased ADMA levels and impaired endothelial function, not only in low-grade inflammation (observed in atherosclerosis) but also in chronic inflammatory diseases, such as rheumatoid arthritis. We also suggest that ADMA is rapidly elevated in response to acute inflammation in healthy individuals and may partly account for inflammation-related endothelial dysfunction. Taken together, these findings imply that ADMA elevation may be a key mechanism by which inflammation induces endothelial dysfunction and identify ADMA as a potential therapeutic target for the treatment of inflammation-related endothelial dysfunction.
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Online Methods Supplement
Assessment of endothelial function FMD and endothelium-independent vasodilatation of the brachial artery were measured as described by Celermajer et al 1 with some modifications, 2 with a linear-array transducer (EnVisor C Philips, L12-3 linear array transducer at 12 MHz). In more details, after 15 minutes rest in supine position in a quiet room with temperature ~22 o C, the brachial artery was scanned in order to quantify its resting diameter. Then a pneumatic cuff placed at the proximal forearm, was inflated to pressure above systolic blood pressure in order to cause ischaemia of the forearm for 5 minutes. Then the cuff was released and the brachial artery was scanned continuously for 2 minutes. After the end of this period, the patient remained in supine position for 10 minutes, and then the brachial artery was re-scanned, sublingual spray of glyceryl trinitrate (GTN, around 200 µg) was administered, and the diameter of the brachial artery was continuously measured for 3 minutes. The diameter of the brachial artery was measured off-line using automated wall tracking software (Vascular Analyser, Medical Imaging Applications LLC). Flow mediated dilation (FMD) was defined as the percent change of brachial artery diameter from rest to the diameter at the 60 th second after the release of the ischaemia cuff. Endothelium independent dilation was defined as the %change of brachial artery diameter from rest to the diameter 3 minutes after the administration of sublingual nitrate.
Measurement Of Systemic Inflammatory Markers And ADMA
Serum interleukin 6 (IL-6) was determined by enzyme-linked immunosorbent assay (ELISA kits by R&D Systems, Wiesbaden-Nordenstadt, Germany), while serum ADMA was also measured by ELISA (DLD Diagnostika GmbH, Hamburg, Germany). 3 The ADMA values derived from ELISA had been correlated with those derived from LC-MS/MS 4 (r=0.98 in 29 healthy individuals, ELISA: 0.72±0.10 vs LC-MS/MS: 0.66±0.08 μmol/L, P=NS), and the absolute ADMA levels reported in the present study were within the range reported in previous studies in healthy individuals 5 and patients with advanced atherosclerosis. 6, 7 The ELISA assays in the 3 studies were run in parallel for the individual study groups. In addition, the cross reactivity of this assay with other arginine analogs is <0.02% for arginine, 1% for nMMA, 1.2% for SDMA and 100% for ADMA, while the intra-and inter-assay variabilities are 4.5% and 8.3% respectively.
Statistical analysis
All continuous variables were tested for normal distribution by using Kolmogorov-Smirnov test. Non-normally distributed variables were log-transformed for analysis and are presented either as logs or in a non-logarithmic format as median[25th-75th percentile]. Normally distributed variables are presented as means±SEM.
Sample size calculations for the second arm of the study revealed that to detect 21% difference in ADMA levels between groups, we will need to study 10 RA patients and 60 controls or CAD patients, with power 90% and α=0.05. For the third study arm, power calculations revealed that with 10 patients in the vaccination study we would be able to detect 25% change in plasma ADMA post vaccination, with α=0.05 and power 90%.
Continuous variables between 3 independent groups were compared by using oneway Analysis of Variance followed by Bonferroni post-hoc correction, while categorical variables were compared by using chi-square test, as appropriate. The effect of vaccination on each variable was compared between the two groups (vaccine-or placebotreated) by using two-way ANOVA for repeated measures with time x treatment interaction. Correlations between continuous variables were assessed by using bivariate analysis, and Pearson's coefficient was estimated.
In multivariate analysis, we used as dependent variable ADMA or FMD as stated, while as independent variables we used those of the demographic characteristics (age, gender, hypertension, diabetes, smoking, hypercholesterolemia, and body mass index) that showed an association with the respective dependent variable in univariate analysis at the level of 15%. A backward elimination procedure was used with p = 0.1 to remove variables from each model. All reported p values were based on 2-sided tests and p<0.05 was considered as significant. SPSS software version 17.0 (SPSS, Inc, Chicago, Illinois) was used for all calculations.
